Mayne Pharma Group Ltd (AU:MYX) — Market Cap & Net Worth
Market Cap & Net Worth: Mayne Pharma Group Ltd (MYX)
Mayne Pharma Group Ltd (AU:MYX) has a market capitalization of $135.09 Million (AU$190.93 Million) as of June 17, 2026. Listed on the AU stock exchange, this Australia-based company holds position #18130 globally and #556 in its home market, demonstrating a 2.17% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mayne Pharma Group Ltd's stock price AU$2.35 by its total outstanding shares 81245827 (81.25 Million). Review Mayne Pharma Group Ltd debt and liabilities to assess the company's total debt and financial obligations.
Mayne Pharma Group Ltd Market Cap History: 2015 to 2026
Mayne Pharma Group Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.53 Billion to $135.09 Million (-17.90% CAGR).
Index Memberships
Mayne Pharma Group Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Australia All Ordinaries
AORD
|
$2.02 Trillion | 0.01% | #295 of 495 |
|
S&P/ASX 300
AXKO
|
$2.17 Trillion | 0.01% | #257 of 300 |
|
ASX Small Ordinaries
AXSO
|
$301.20 Billion | 0.04% | #165 of 200 |
Weight: Mayne Pharma Group Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mayne Pharma Group Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mayne Pharma Group Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.44x
Mayne Pharma Group Ltd's market cap is 0.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.54 Billion | $267.28 Million | $37.35 Million | 5.75x | 41.15x |
| 2017 | $794.23 Million | $572.60 Million | $88.57 Million | 1.39x | 8.97x |
| 2018 | $885.66 Million | $530.31 Million | -$133.98 Million | 1.67x | N/A |
| 2019 | $497.11 Million | $525.21 Million | -$279.20 Million | 0.95x | N/A |
| 2020 | $394.26 Million | $456.99 Million | -$92.79 Million | 0.86x | N/A |
| 2021 | $337.12 Million | $400.78 Million | -$208.42 Million | 0.84x | N/A |
| 2022 | $228.56 Million | $157.15 Million | -$281.29 Million | 1.45x | N/A |
| 2023 | $353.54 Million | $183.59 Million | $117.25 Million | 1.93x | 3.02x |
| 2024 | $285.71 Million | $388.15 Million | -$174.23 Million | 0.74x | N/A |
| 2025 | $178.78 Million | $408.10 Million | -$93.84 Million | 0.44x | N/A |
Competitor Companies of MYX by Market Capitalization
Companies near Mayne Pharma Group Ltd in the global market cap rankings as of June 17, 2026.
Key companies related to Mayne Pharma Group Ltd by market ranking:
- McKesson Corporation (NYSE:MCK): Ranked #271 globally with a market cap of $94.41 Billion USD.
- Cencora Inc. (NYSE:COR): Ranked #538 globally with a market cap of $50.53 Billion USD.
- Cardinal Health Inc (NYSE:CAH): Ranked #640 globally with a market cap of $43.01 Billion USD.
- Sigma Healthcare Ltd (AU:SIG): Ranked #1151 globally with a market cap of $22.95 Billion USD ( AU$32.44 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #271 | McKesson Corporation | NYSE:MCK | $94.41 Billion | $785.43 |
| #538 | Cencora Inc. | NYSE:COR | $50.53 Billion | $281.46 |
| #640 | Cardinal Health Inc | NYSE:CAH | $43.01 Billion | $227.72 |
| #1151 | Sigma Healthcare Ltd | AU:SIG | $22.95 Billion | AU$2.81 |
Mayne Pharma Group Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Mayne Pharma Group Ltd's market cap moved from $1.53 Billion to $ 135.09 Million, with a yearly change of -17.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$135.09 Million | -24.44% |
| 2025 | AU$178.78 Million | -37.42% |
| 2024 | AU$285.71 Million | -19.19% |
| 2023 | AU$353.54 Million | +54.69% |
| 2022 | AU$228.56 Million | -32.20% |
| 2021 | AU$337.12 Million | -14.49% |
| 2020 | AU$394.26 Million | -20.69% |
| 2019 | AU$497.11 Million | -43.87% |
| 2018 | AU$885.66 Million | +11.51% |
| 2017 | AU$794.23 Million | -48.33% |
| 2016 | AU$1.54 Billion | +0.48% |
| 2015 | AU$1.53 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Mayne Pharma Group Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $135.09 Million USD |
| MoneyControl | $135.09 Million USD |
| MarketWatch | $135.09 Million USD |
| marketcap.company | $135.09 Million USD |
| Reuters | $135.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mayne Pharma Group Ltd
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract developmen… Read more